Iovance Biotherapeutics, Inc. (IOVA) is a Biotechnology company in the Healthcare sector, currently trading at $3.64. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is IOVA = $2 (-45.1% upside).
Valuation: IOVA trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.07.
Financials: revenue is $264M, +6879.8%/yr average growth. Net income is $391M (loss), growing at -0.3%/yr. Net profit margin is -148.4% (negative). Gross margin is 97.2% (+901.7 pp trend).
Balance sheet: total debt is $48M against $699M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 3.2 (strong liquidity). Debt-to-assets is 5.3%. Total assets: $913M.
Analyst outlook: 15 / 20 analysts rate IOVA as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 49/100 (Partial), Income 10/100 (Fail).
